Adding bemarituzumab to chemotherapy improves outcomes in certain gastric cancers

The addition of bemarituzumab to modified FOLFOX6 benefited patients with advanced gastric and gastroesophageal junction cancer with FGFR2b overexpression, according to data presented at Gastrointestinal Cancers Symposium.“Bemarituzumab [FPA144, Five Prime Therapeutics] is a first-in-class humanized IgG1 monoclonal antibody that selectively binds to FGFR2b, inhibits ligand binding and mediates antibody-dependent cell-mediated cytotoxicity,” Zev A. Wainberg, MD, assistant professor of medicine and co-director of the gastrointestinal oncology program at University of California, LosRead More

Share on facebook
Share on twitter
Share on linkedin